Barclays analyst Leon Wang raised the firm’s price target on MoonLake Immunotherapeutics to $41 from $28 and keeps an Equal Weight rating on the shares. The firm said Moonlake highlighted MIRA results recently, with SLK demonstrated clear efficacy and in-line safety. Wang added that SLK looks ultimately approvable if these data are recapitulated in a phase 3 trial, which would justify a higher valuation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MLTX:
- MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering
- MoonLake Immunotherapeutics files to sell $250M in common stock
- MoonLake price target doubled to $56 from $28 at SVB Securities
- âStrong’ competitor data sends Acelyrin to the moon
- MoonLake data provide validation for Acelyrin, says Morgan Stanley